Decoy Therapeutics (NASDAQ:DCOY – Get Free Report) saw a significant decline in short interest in October. As of October 15th, there was short interest totaling 97,605 shares, a decline of 35.1% from the September 30th total of 150,336 shares. Currently, 4.2% of the shares of the stock are sold short. Based on an average daily volume of 119,437 shares, the days-to-cover ratio is currently 0.8 days.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Decoy Therapeutics in a research note on Wednesday, September 9th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $30.00.
Get Our Latest Stock Analysis on Decoy Therapeutics
Decoy Therapeutics Price Performance
Decoy Therapeutics stock opened at $1.07 on Monday. The firm has a market capitalization of $2.56 million, a P/E ratio of -0.04 and a beta of 0.76. The stock has a fifty day moving average price of $2.16 and a two-hundred day moving average price of $5.39. Decoy Therapeutics has a 52-week low of $0.90 and a 52-week high of $47.28.
Decoy Therapeutics (NASDAQ:DCOY – Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($4.46) EPS for the quarter. The firm had revenue of $0.23 million for the quarter. On average, equities research analysts predict that Decoy Therapeutics will post -8.96 EPS for the current fiscal year.
About Decoy Therapeutics
Decoy Therapeutics is a biotechnology company developing messenger RNA (mRNA)-based medicines. Its technology is intended to direct the body’s cells to produce therapeutic proteins, with the goal of addressing diseases through targeted biological mechanisms.
The company’s research activities focus on applying its mRNA platform to potential treatments in areas including infectious disease and oncology. Its pipeline remains centered on investigational programs, and the company’s products are subject to the development, testing and regulatory approval processes required for biotechnology therapies.
Publicly available information about Decoy Therapeutics’ operating history, geographic presence and leadership is limited.
Read More
- Five stocks we like better than Decoy Therapeutics
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
- Exxon’s Refining Profits Soared—Did Chevron Get the Same Windfall?
- Eli Lilly’s First Full Medicare Quarter: Is Volume Still Outrunning Price Cuts?
- Oracle’s AI Spending Peak Is in Sight—Can the Stock Recover?
Receive News & Ratings for Decoy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Decoy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
